Boston Scientific Divests Specialty Pharma Business
The $800m sale of BTG Specialty Pharmaceuticals business to SERB leaves Boston Scientific with BTG’s successful interventional oncology and vascular products.
The $800m sale of BTG Specialty Pharmaceuticals business to SERB leaves Boston Scientific with BTG’s successful interventional oncology and vascular products.